Because readers are likely to encounter and assess individual publications, NHS EED abstracts reflect the original publication as it is written, as a stand-alone paper. Where NHS EED abstractors are able to identify positively that a publication is significantly linked to or informed by other publications, these will be referenced in the text of the abstract and their bibliographic details recorded here for information.
Perez-Marreno R, Chu FM, Gleason D, et al. A six month, open label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 2002;24:1902-13.
Chu FM, Jayson M, Dineen MK, et al. A clinical study of 22.5 mg. La-2250: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168:1199-203.
Crawford DE, Sartor O, Chu F, et al. A 12 month clinical study of LA-2585(45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533-6.
Alloul K, Sauriol L, Lafortune L. Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma. Can J Urol 1998;5:585-94.